Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 2, 2024
-Company to also host virtual webcast with a cardiology business update- MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call...
-
Sep 27, 2024
Boston Scientific Corporation (NYSE: BSX) announced it has received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The...
-
Sep 17, 2024
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke...
-
Sep 17, 2024
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the indication for current-generation INGEVITY™+ Pacing Leads – thin wires...
-
Aug 27, 2024
Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology...
-
Aug 13, 2024
Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 2024 Healthcare Conference on Wednesday, September 4, 2024. Mike Mahoney, chairman and chief executive officer, and Dr....
-
Jul 30, 2024
Boston Scientific Corporation (NYSE: BSX) announced today the election of David Habiger to its board of directors, effective immediately. Habiger has more than 30 years of business leadership...
-
Jul 24, 2024
Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis...
-
Jul 15, 2024Five-year pooled results for Intracept™ Intraosseous Nerve Ablation System demonstrate significant pain and function improvements in patients with vertebrogenic low back pain
MARLBOROUGH, Mass. and MIAMI BEACH, Fla. July 15, 2024 – Boston Scientific Corporation (NYSE: BSX) today announced the presentation of positive five-year pooled results for the Intracept™...
-
Jul 8, 2024Boston Scientific to Present Key Data at the 2024 American Society of Pain & Neuroscience Conference
MARLBOROUGH, Mass., July 8, 2024 -- Boston Scientific Corporation (NYSE: BSX) today announced the company’s clinical data will be featured at the sixth annual American Society of Pain &...
-
Jul 1, 2024
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2024, on Wednesday, July 24,...
-
Jun 18, 2024
Acquisition adds innovative technology for stroke prevention to vascular portfolio MARLBOROUGH, Mass., June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it...
-
May 18, 2024
Additional data from APPRAISE ATP trial reinforce modular therapy approach with EMBLEM™ Subcutaneous Implantable Defibrillator and EMPOWER™ Leadless Pacemaker MARLBOROUGH, Mass., May 18, 2024...
-
May 8, 2024
Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately. Dr. Pegus has more than 25 years of clinical and...
-
May 1, 2024
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May. On May 14, 2024, Dan Brennan, executive vice president and chief financial officer, and Ken...
-
Apr 24, 2024
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis...
-
Apr 8, 2024Learn about the study of FARAVIEW™ Software Module and FARAWAVE™ Nav Pulsed Field Ablation Catheter for patients with paroxysmal and persistent AFib.
Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation...
-
Apr 1, 2024
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2024, on Wednesday, April 24,...
-
Mar 1, 2024
First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/...
-
Feb 27, 2024
Boston Scientific Corporation (NYSE: BSX) (the "Company") today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of...
-
Feb 22, 2024
Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of...
-
Feb 6, 2024Supported by the positive one-year SOLIS randomized control trial results
MARLBOROUGH, Mass., Feb. 6, 2024 -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter ™
-
Feb 5, 2024
Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6, 2024. Mike Mahoney, chairman and chief executive officer, will...
-
Jan 31, 2024
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis...
-
Jan 31, 2024
Strong clinical evidence base, largest volume of real-world use reinforce safety, efficacy and efficiency advantages of the system MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston...
-
Jan 20, 2024Late-breaking data from the SOLIS study demonstrated sustained pain relief at one-year interval with spinal cord stimulation
MARLBOROUGH, Mass. and LAS VEGAS, Jan. 20, 2024 – Boston Scientific Corporation (NYSE: BSX) today announced positive one-year results from the SOLIS randomized control trial, demonstrating...
-
Jan 11, 2024
MARLBOROUGH, Mass., Jan. 11, 2024 -- Boston Scientific Corporation (NYSE: BSX) today announced the company’s clinical data that will be featured at the 27th North American Neuromodulation...
-
Jan 8, 2024
Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass., Jan. 8, 2024 /PRNewswire/ -- Boston Scientific Corporation...
-
Jan 5, 2024
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023, on Wednesday,...
-
Dec 28, 2023
Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System* as a...
-
Nov 17, 2023
Recent healthcare plan coverage of Intracept® system expands access to vertebrogenic pain treatment for tens of millions of patients MARLBOROUGH, Mass., Nov. 17, 2023 /PRNewswire/ -- Boston...
-
Nov 1, 2023
Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2023 Healthcare Conference on Tuesday, November 14, 2023. Dan Brennan, executive vice president and chief financial officer,...
-
Oct 26, 2023
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational1 basis...
-
Oct 25, 2023
Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB MARLBOROUGH, Mass. and SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ --...
-
Oct 24, 2023
Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ --...
-
Oct 11, 2023Nearly 50% of American adults living with diabetes will be affected by diabetic neuropathy complications in their lifetimei
MARLBOROUGH, Mass., Oct. 11, 2023 -- Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter Alpha™...
-
Oct 2, 2023
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday,...
-
Sep 19, 2023
Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain MARLBOROUGH, Mass., Sept. 19, 2023 /PRNewswire/ -- Boston...
-
Sep 6, 2023
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific...
-
Sep 5, 2023
Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 20, 2023, between...
-
Aug 27, 2023
Noninferiority established through high treatment success, low adverse event rates Findings presented at ESC Congress 2023 and simultaneously published in The New England Journal of Medicine...
-
Aug 8, 2023
First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems MARLBOROUGH, Mass., Aug. 8, 2023 /PRNewswire/ -- Boston...
-
Jul 27, 2023
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational1 basis...
-
Jul 11, 2023
Boston Scientific Position on FDA Update About Use of Paclitaxel-Coated Devices to Treat Peripheral Arterial Disease On July 11, 2023, the U.S. Food and Drug Administration (FDA) published a...
-
Jul 11, 2023Vercise™ Neural Navigator 5 with STIMVIEW™ XT Technology is designed to provide intuitive therapy management
MARLBOROUGH, Mass., Jul. 11, 2023 -- Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration (FDA) approval for the Vercise™ Neural Navigator 5 Software,...
-
Jun 28, 2023
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2023 on Thursday, July 27,...
-
Jun 27, 2023
Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each effective immediately. Dr. Mega is the co-founder...
-
May 30, 2023
Boston Scientific Corporation (NYSE: BSX) announced today that its Series A 5.50% Mandatory Convertible Preferred Stock (the preferred stock) will automatically convert into shares of the...
-
May 20, 2023
Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* Results from global trial of the POLARx™...
-
May 15, 2023
Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023. Mike Mahoney, chairman and chief executive officer,...